CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“GBM”). On average, GBM is nearly 100% fatal just over a year into diagnosis. “CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment in the country…. France’s approval comes on the heels of similar authorization in Switzerland, where Swissmedic, the Swiss agency for therapeutic products, joined swissethics, the umbrella organization of the cantonal Ethics Committees (‘ECs’), in greenlighting the clinical studies,” a recent article reads. “‘The data Berubicin has shown to date demonstrates encouraging promise in treatment of GBM. Patients and families are desperate for a viable treatment option that provides benefits, and I look forward to further exploring Berubicin’s potential,’ stated CNS’s national coordinating investigator partner in Switzerland, Professor Michael Weller, MD, of the University Hospital Zurich.”
To view the full article, visit https://ibn.fm/OIXZ6
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork